America’s Growing Drug Overdose Crisis
Time & Location
More than 107,000 Americans died of drug overdoses last year - a record high. However, some populations are disproportionately affected with overdose deaths, with deaths increasing faster among Black and Indigenous people. Prevention and harm reduction efforts, such as increasing access to naloxone (the antidote to opioid overdoses), sterile needles, drug test strips, and supervised consumption sites, can reduce the toll of the overdose crisis. Additionally, there is a need to increase access to treatment and support recovery for people struggling with substance use disorder.
In this webinar, we heard from public health leaders who are addressing the drug overdose crisis. Speakers discussed:
- The latest research on the drug overdose crisis, including stimulants, and the role of synthetic opioids, such as fentanyl
- How evidence-based prevention and harm reduction solutions can lower the risk of death or acquiring infectious diseases
- The need to ensure equal access to treatment and culturally responsive care to address the overdose crisis
Wilson Compton, MD, MPE
Deputy Director of the National Institute on Drug Abuse
Edwin Chapman, MD
Internal Medicine and Addiction Medicine Practitioner
Christine Bracamonte Wiggs, PhD, MPH, MS
Staff Vice President, Community & Health Advancement at Blue Cross Blue Shield of Arizona
Opportunities to Improve Opioid Use Disorder and Infectious Disease Services; Integrating Responses to a Dual Epidemic, National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on the Examination of the Integration of Opioid and Infectious Disease Prevention Efforts in Select Programs, National Academies Press (US); 2020 Jan 23.
Pharmacogenomics-guided policy in opioid use disorder (OUD) management: An ethnically-diverse case-based approach. Ettienne EB, Chapman E, Maneno M, Ofoegbu A, Wilson B, Settles-Reaves B, Clarke M, Dunston G, Rosenblatt K. Addict Behav Rep. 2017 May 8.
Pharmacogenomics and Opioid Use Disorder: Clinical Decision Support in an African American Cohort. Earl B. Ettienne, Adaku Ofoegbu, Mary K. Maneno, Jayla Briggs, Ginikannwa Ezeude, Simisola Williams, Casey Walker, Edwin Chapman, Journal of the National Medical Association, Volume 111, Issue 6,
Buprenorphine Dose Limits: What is the Evidence? ASAM 53rd Annual Conference, April 1, 2022.
The Opioid Epidemic: a Crisis Disproportionately Impacting Black Americans and Urban Communities. Gondré-Lewis MC, Abijo T, Gondré-Lewis TA. J Racial Ethn Health Disparities. 2022 Sep 6.
Heroin overdoses are vanishing from D.C. The reason? Fentanyl. Washington Post, Peter Jamison, September 8, 2022.
Black Opioid Deaths Increase Faster Than Whites, Spurring Calls For Treatment Equity. Marisa Peñaloza. September 10, 2021.
United States House of Representatives
Committee on Ways and Means Hearing on “Substance Use, Suicide Risk, and the American Health System.” March 2, 2022. Testimony of Edwin C Chapman, MD
Pharmacogenomics and Opioid Use Disorder: Clinical Decision Support in an African American Cohort. Ettienne EB, Ofoegbu A, Maneno MK, Briggs J, Ezeude G, Williams S, Walker C, Chapman E. J Natl Med Assoc. 2019 Dec.
State Variation in Medicaid Prescriptions for Opioid Use Disorder from 2011 to 2018. Lisa Clemans-Cope, Victoria Lynch, Emma Winiski, and Marni Epstein. August 2019.
Integrating MOUD into Primary Care: Medicaid Strategies for Improving Treatment Engagement and Outcomes and Reducing Disparities. Foundation for Opioid Response Efforts. Rutgers 4/28/21.
Policies Should Promote Access to Buprenorphine for Opioid Use Disorder. Pew Charitable Trusts. May 24, 2021.
“Dopesick” Author Beth Macy Talks About Her New Book, “Raising Lazarus” Washingtonian, Sept 13, 2022
More Related Content
See More on: Substance Use